Publication

Impact of pneumococcal conjugate vaccine on otitis media

Authored by:

Fireman, B., Black, S.B., Shinefield, H.R., et al.

Full Citation:

Fireman, B., Black, S.B., Shinefield, H.R., et al. 2003. Impact of pneumococcal conjugate vaccine on otitis media. Pediatric Infectious Disease Journal. 22(1).

View Publication

Additional key concepts from this publication:

Use of vaccines decreases the need to use antibiotics to treat disease, thus reducing the opportunity for the development of antimicrobial resistance.

Key Evidence: In a study evaluating the impact of PCV7 on 40,000 recipients and control subjects in northern California revealed that the vaccine could significantly decrease the need for antibiotics to treat the disease. The children who had received the vaccine displayed a 5.4% reduction in the number of antibiotic prescriptions and a 12.6% reduction in the use of “second-line antibiotics” compared to the controls. Additionally, when looking at children in the time period between their first dose and attainment of the age of 3.5 years, receiving the vaccine had prevented 35 antibiotic prescriptions per 100 fully vaccinated children.

Use of vaccines decreases the need to use health services and treatments, like antibiotics, to treat disease.

Key Evidence: In a study of nearly 40,000 recipients of PCV7 and control subjects in northern California, there was a 5.4% reduction in the number of antibiotic prescriptions and a 12.6% reduction in the use of “second-line antibiotics” among children who received the pneumococcal conjugate vaccine. Between the time the first dose was administered and the age of 3.5 years, use of the vaccine prevented 35 antibiotic prescriptions per 100 fully vaccinated children.